Search results for: Oncology

Review of Plans for Refining Patient-Reported Outcomes Measures

19 February 2013

…the EuroQol Group’s scientific research agenda for the coming year and plans for the EQ-5D-5L approach to measuring patient-reported outcomes of care. Health technology assessment affects patients’ access to oncology…

Patrick Hopkinson

14 May 2026

…he served as a NICE Appeal Panel member for 10 years. Previously he worked at GSK in Global and Country roles and as a Clinical Oncology Pharmacist in the UK…

OHE Study on Pharmaceutical R&D Costs Released

3 December 2012

…600% from the 1970s[3] to the 2000s[4]. Second, success rates for clinical development are falling as tougher therapeutic areas are tackled—e.g. neurology (Alzheimer’s), autoimmune diseases (arthritis), and oncology. Success rates…

Spotlight on OHE: Valuing Spillovers, End-of-Life Decisions and Hospital Outcomes

20 March 2012

…of life. At the Second Annual Oncology Market and Patient Access conference in January, Dr. Jorge Mestre-Ferrandiz presented preliminary results from OHE research in progress. It analyses appraisals of cancer…

OHE Lunchtime Seminar: Health Technology Assessment Scientific and Outcomes Advice on Medicinal Drug Development

4 October 2016, 11:00pm

…also developed the NICE scientific advice database. Prior to NICE Francois worked for the EMA for 15 years. His activities covered both pre- (registration of centrally authorised products in oncology,…

OHE at ISPOR Europe 2018

…Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology In the economic modelling of immunotherapies, the question arises of which utilities should be assigned…

CBO Doesn’t Capture The Real Impact of H.R. 3 on Innovation 

14 September 2021

…transformative effect that they have had in areas like oncology and genetic diseases. In these complex diseases, understanding of the disease and how therapeutics could prevent or alleviate the disease,…

Cost-Effectiveness Thresholds and Expert Elicitation: a Bridge Too Far?

29 April 2021

…observe how changes in mortality rates in oncology might relate to changes in mortality rates in mental health. The authors also asked clinicians to assess values for a range of…

Dementia: The R&D Landscape

1 November 2015

…observations include: R&D costs are higher for neurology and Alzheimer’s disease (AD) (as well as respiratory and oncology) than other therapy areas Higher costs are likely due to lower success…